Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Change in Taxes: 2013-2017

Historic Change in Taxes for Amphastar Pharmaceuticals (AMPH) over the last 4 years, with Sep 2017 value amounting to -$2.5 million.

  • Amphastar Pharmaceuticals' Change in Taxes fell 351.29% to -$2.5 million in Q3 2017 from the same period last year, while for Sep 2017 it was -$5.8 million, marking a year-over-year decrease of 236.88%. This contributed to the annual value of -$92,000 for FY2015, which is 116.46% down from last year.
  • Latest data reveals that Amphastar Pharmaceuticals reported Change in Taxes of -$2.5 million as of Q3 2017, which was up 22.11% from -$3.2 million recorded in Q2 2017.
  • In the past 5 years, Amphastar Pharmaceuticals' Change in Taxes ranged from a high of $6.0 million in Q4 2014 and a low of -$7.3 million during Q3 2014.
  • For the 3-year period, Amphastar Pharmaceuticals' Change in Taxes averaged around -$209,000, with its median value being -$193,500 (2015).
  • Per our database at Business Quant, Amphastar Pharmaceuticals' Change in Taxes skyrocketed by 15,137.50% in 2014 and then tumbled by 351.29% in 2017.
  • Amphastar Pharmaceuticals' Change in Taxes (Quarterly) stood at -$40,000 in 2013, then spiked by 15,137.50% to $6.0 million in 2014, then tumbled by 83.52% to $991,000 in 2015, then increased by 21.84% to -$544,000 in 2016, then tumbled by 351.29% to -$2.5 million in 2017.
  • Its last three reported values are -$2.5 million in Q3 2017, -$3.2 million for Q2 2017, and $394,000 during Q1 2017.